The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Adding Tislelizumab to Chemo Enhances OS Benefit in PD-L1+ Esophageal Squamous Cell Carcinoma
Findings from the RATIONALE-306 trial support treatment of tislelizumab plus chemotherapy for PD-L1-positive ESCC.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Opinion: Novel Risk Assessment Tool Helps Predict Cisplatin-Induced Acute Kidney Injury
Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.
Adding Tislelizumab to Chemo Enhances OS Benefit in PD-L1+ Esophageal Squamous Cell Carcinoma
Findings from the RATIONALE-306 trial support treatment of tislelizumab plus chemotherapy for PD-L1-positive ESCC.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Opinion: Novel Risk Assessment Tool Helps Predict Cisplatin-Induced Acute Kidney Injury
Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.
Latest Conference Coverage
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Durvalumab Plus Chemo Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer